ArticleCancers2019
Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma.Cell death discovery · 2025Article
- Pathogenic Germline Variants in Uveal Melanoma Driver and BAP1-Associated Genes in Finnish Patients with Uveal Melanoma.Pigment cell & melanoma research · 2025Article
- The Current State of Systemic Therapy of Metastatic Uveal Melanoma.American journal of clinical dermatology · 2024Review
- Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis.Cancers · 2024Review
- Machine Learning Methods for Gene Selection in Uveal Melanoma.International journal of molecular sciences · 2024Article
- Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis.International journal of molecular sciences · 2023Article
- Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma.Cancers · 2023Article
- Review
- Article
- Specific human endogenous retroviruses predict metastatic potential in uveal melanoma.JCI insight · 2022Article
- Where Do We Stand in Regularization for Life Science Studies?Journal of computational biology : a journal of computational molecular cell biology · 2022Article
- Uveal Melanoma Metastasis.Cancers · 2021Review
- Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.Nature genetics · 2021Article
- Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma.Molecular biomedicine · 2021Review
- Review
- Recent advancements in the management of retinoblastoma and uveal melanoma.Faculty reviews · 2021Review
- Construction and Validation of a Novel Immunosignature for Overall Survival in Uveal Melanoma.Frontiers in cell and developmental biology · 2021Article
- Update onCancers · 2020Review
- Uveal Melanoma.Cancers · 2019Article
- Transcriptomic Analysis of Metastatic Uveal Melanoma and Differences in Male and Female Patients.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundUveal melanoma (UM), a rare cancer of the eye, is characterized by initiating mutations in the genes G-protein subunit alpha Q (
methodsWe analyzed all the 4125 mutations detected in exome sequencing datasets, comprising a total of 139 Ums, and tested the enrichment of secondary drivers in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that also contained the initiating mutations. We searched for additional mutations in the putative secondary driver gene protein tyrosine kinase 2 beta (
resultsSecondary drivers were significantly enriched in KEGG pathways that also contained
conclusionsA considerable part of rare mutations that occur in addition to known driver mutations are likely to affect tumor development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.